The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production

Radoslaw S. Zagozdzon, Adam Giermasz, Jakub Golab, Tomasz Stoklosa, Ahmad Jalili, Marek Jakóbisiak

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In our recent study we described a significant antileukemic efficacy of a combination therapy with interleukin-12 (IL-12) and doxorubicin (DOX) in the L1210 leukemia model. This therapeutic effect was abrogated by elimination of activated macrophages. Activated macrophages produce a variety of factors that can contribute to the elimination of tumor cells in vivo, including proteases, TNF, reactive oxygen intermediates, and nitric oxide (NO). Based on the results of previous reports, the contribution of NO in potentiated antileukemic effects of IL-12+DOX combination seemed to be highly possible. Both DOX and IL-12 given alone increased the production of NO by peritoneal macrophages, however, macrophages derived from the mice treated with the combination of those agents produced significantly less NO than macrophages from IL-12-alone-treated mice. Production of NO by spleen macrophages after IL-12+DOX treatment was higher than it was in controls, IL-12-alone- or DOX-alone-treated groups. In serum, concentrations of NO(x)- in IL-12- or IL-12+DOX-treated mice were significantly higher in comparison with controls, however not significantly different from each other. Addition of L-NAME treatment to the IL-12+DOX therapy in leukemia-bearing mice did not significantly change the antileukemic efficacy of this therapy. Thus, our results indicate that the augmented antileukemic effects of IL-12+DOX combination therapy in L1210 model are NO-independent. Therefore, further studies on the possible mechanisms of potentiated antileukemic activity of combination of IL-12 and DOX would be worth pursuing. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)67-75
Number of pages9
JournalCancer Letters
Volume147
Issue number1-2
DOIs
StatePublished - Dec 1 1999
Externally publishedYes

Fingerprint

Interleukin-12
Doxorubicin
Nitric Oxide
Macrophages
Leukemia L1210
NG-Nitroarginine Methyl Ester
Peritoneal Macrophages
Therapeutic Uses
Therapeutics
Leukemia
Peptide Hydrolases
Spleen
Oxygen

Keywords

  • Chemoimmunotherapy
  • Leukemia
  • Mouse
  • Nitric oxide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. / Zagozdzon, Radoslaw S.; Giermasz, Adam; Golab, Jakub; Stoklosa, Tomasz; Jalili, Ahmad; Jakóbisiak, Marek.

In: Cancer Letters, Vol. 147, No. 1-2, 01.12.1999, p. 67-75.

Research output: Contribution to journalArticle

Zagozdzon, Radoslaw S. ; Giermasz, Adam ; Golab, Jakub ; Stoklosa, Tomasz ; Jalili, Ahmad ; Jakóbisiak, Marek. / The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. In: Cancer Letters. 1999 ; Vol. 147, No. 1-2. pp. 67-75.
@article{26291cbb46b54e829c5cf3cd0653ba8e,
title = "The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production",
abstract = "In our recent study we described a significant antileukemic efficacy of a combination therapy with interleukin-12 (IL-12) and doxorubicin (DOX) in the L1210 leukemia model. This therapeutic effect was abrogated by elimination of activated macrophages. Activated macrophages produce a variety of factors that can contribute to the elimination of tumor cells in vivo, including proteases, TNF, reactive oxygen intermediates, and nitric oxide (NO). Based on the results of previous reports, the contribution of NO in potentiated antileukemic effects of IL-12+DOX combination seemed to be highly possible. Both DOX and IL-12 given alone increased the production of NO by peritoneal macrophages, however, macrophages derived from the mice treated with the combination of those agents produced significantly less NO than macrophages from IL-12-alone-treated mice. Production of NO by spleen macrophages after IL-12+DOX treatment was higher than it was in controls, IL-12-alone- or DOX-alone-treated groups. In serum, concentrations of NO(x)- in IL-12- or IL-12+DOX-treated mice were significantly higher in comparison with controls, however not significantly different from each other. Addition of L-NAME treatment to the IL-12+DOX therapy in leukemia-bearing mice did not significantly change the antileukemic efficacy of this therapy. Thus, our results indicate that the augmented antileukemic effects of IL-12+DOX combination therapy in L1210 model are NO-independent. Therefore, further studies on the possible mechanisms of potentiated antileukemic activity of combination of IL-12 and DOX would be worth pursuing. Copyright (C) 1999 Elsevier Science Ireland Ltd.",
keywords = "Chemoimmunotherapy, Leukemia, Mouse, Nitric oxide",
author = "Zagozdzon, {Radoslaw S.} and Adam Giermasz and Jakub Golab and Tomasz Stoklosa and Ahmad Jalili and Marek Jak{\'o}bisiak",
year = "1999",
month = "12",
day = "1",
doi = "10.1016/S0304-3835(99)00277-3",
language = "English (US)",
volume = "147",
pages = "67--75",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production

AU - Zagozdzon, Radoslaw S.

AU - Giermasz, Adam

AU - Golab, Jakub

AU - Stoklosa, Tomasz

AU - Jalili, Ahmad

AU - Jakóbisiak, Marek

PY - 1999/12/1

Y1 - 1999/12/1

N2 - In our recent study we described a significant antileukemic efficacy of a combination therapy with interleukin-12 (IL-12) and doxorubicin (DOX) in the L1210 leukemia model. This therapeutic effect was abrogated by elimination of activated macrophages. Activated macrophages produce a variety of factors that can contribute to the elimination of tumor cells in vivo, including proteases, TNF, reactive oxygen intermediates, and nitric oxide (NO). Based on the results of previous reports, the contribution of NO in potentiated antileukemic effects of IL-12+DOX combination seemed to be highly possible. Both DOX and IL-12 given alone increased the production of NO by peritoneal macrophages, however, macrophages derived from the mice treated with the combination of those agents produced significantly less NO than macrophages from IL-12-alone-treated mice. Production of NO by spleen macrophages after IL-12+DOX treatment was higher than it was in controls, IL-12-alone- or DOX-alone-treated groups. In serum, concentrations of NO(x)- in IL-12- or IL-12+DOX-treated mice were significantly higher in comparison with controls, however not significantly different from each other. Addition of L-NAME treatment to the IL-12+DOX therapy in leukemia-bearing mice did not significantly change the antileukemic efficacy of this therapy. Thus, our results indicate that the augmented antileukemic effects of IL-12+DOX combination therapy in L1210 model are NO-independent. Therefore, further studies on the possible mechanisms of potentiated antileukemic activity of combination of IL-12 and DOX would be worth pursuing. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - In our recent study we described a significant antileukemic efficacy of a combination therapy with interleukin-12 (IL-12) and doxorubicin (DOX) in the L1210 leukemia model. This therapeutic effect was abrogated by elimination of activated macrophages. Activated macrophages produce a variety of factors that can contribute to the elimination of tumor cells in vivo, including proteases, TNF, reactive oxygen intermediates, and nitric oxide (NO). Based on the results of previous reports, the contribution of NO in potentiated antileukemic effects of IL-12+DOX combination seemed to be highly possible. Both DOX and IL-12 given alone increased the production of NO by peritoneal macrophages, however, macrophages derived from the mice treated with the combination of those agents produced significantly less NO than macrophages from IL-12-alone-treated mice. Production of NO by spleen macrophages after IL-12+DOX treatment was higher than it was in controls, IL-12-alone- or DOX-alone-treated groups. In serum, concentrations of NO(x)- in IL-12- or IL-12+DOX-treated mice were significantly higher in comparison with controls, however not significantly different from each other. Addition of L-NAME treatment to the IL-12+DOX therapy in leukemia-bearing mice did not significantly change the antileukemic efficacy of this therapy. Thus, our results indicate that the augmented antileukemic effects of IL-12+DOX combination therapy in L1210 model are NO-independent. Therefore, further studies on the possible mechanisms of potentiated antileukemic activity of combination of IL-12 and DOX would be worth pursuing. Copyright (C) 1999 Elsevier Science Ireland Ltd.

KW - Chemoimmunotherapy

KW - Leukemia

KW - Mouse

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=0032735890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032735890&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(99)00277-3

DO - 10.1016/S0304-3835(99)00277-3

M3 - Article

C2 - 10660091

AN - SCOPUS:0032735890

VL - 147

SP - 67

EP - 75

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1-2

ER -